499 related articles for article (PubMed ID: 24750101)
21. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.
Leger AJ; Jacques SL; Badar J; Kaneider NC; Derian CK; Andrade-Gordon P; Covic L; Kuliopulos A
Circulation; 2006 Mar; 113(9):1244-54. PubMed ID: 16505172
[TBL] [Abstract][Full Text] [Related]
22. The contribution of thrombin-induced platelet activation to thrombus growth is diminished under pathological blood shear conditions.
Lee H; Sturgeon SA; Jackson SP; Hamilton JR
Thromb Haemost; 2012 Feb; 107(2):328-37. PubMed ID: 22187047
[TBL] [Abstract][Full Text] [Related]
23. The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1.
Poullis M; Manning R; Laffan M; Haskard DO; Taylor KM; Landis RC
J Thorac Cardiovasc Surg; 2000 Aug; 120(2):370-8. PubMed ID: 10917956
[TBL] [Abstract][Full Text] [Related]
24. Thrombin receptor levels in platelet concentrates during storage and their impact on platelet functionality.
Schlagenhauf A; Kozma N; Leschnik B; Wagner T; Muntean W
Transfusion; 2012 Jun; 52(6):1253-9. PubMed ID: 22233332
[TBL] [Abstract][Full Text] [Related]
25. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
Whellan DJ; Tricoci P; Chen E; Huang Z; Leibowitz D; Vranckx P; Marhefka GD; Held C; Nicolau JC; Storey RF; Ruzyllo W; Huber K; Sinnaeve P; Weiss AT; Dery JP; Moliterno DJ; Van de Werf F; Aylward PE; White HD; Armstrong PW; Wallentin L; Strony J; Harrington RA; Mahaffey KW
J Am Coll Cardiol; 2014 Mar; 63(11):1048-57. PubMed ID: 24211500
[TBL] [Abstract][Full Text] [Related]
26. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.
Wielders SJ; Bennaghmouch A; Reutelingsperger CP; Bevers EM; Lindhout T
J Thromb Haemost; 2007 Mar; 5(3):571-6. PubMed ID: 17166251
[TBL] [Abstract][Full Text] [Related]
27. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
[TBL] [Abstract][Full Text] [Related]
28. Thrombin-induced platelet PAR4 activation: role of glycoprotein Ib and ADP.
Adam F; Verbeuren TJ; Fauchère JL; Guillin MC; Jandrot-Perrus M
J Thromb Haemost; 2003 Apr; 1(4):798-804. PubMed ID: 12871418
[TBL] [Abstract][Full Text] [Related]
29. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Lee CY; Teng CM
Thromb Haemost; 2002 Jun; 87(6):1026-33. PubMed ID: 12083482
[TBL] [Abstract][Full Text] [Related]
30. Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIbα.
Carrim N; Arthur JF; Hamilton JR; Gardiner EE; Andrews RK; Moran N; Berndt MC; Metharom P
Redox Biol; 2015 Dec; 6():640-647. PubMed ID: 26569550
[TBL] [Abstract][Full Text] [Related]
31. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
[TBL] [Abstract][Full Text] [Related]
32. The role of PAR4 in thrombin-induced thromboxane production in human platelets.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Teng CM
Thromb Haemost; 2003 Aug; 90(2):299-308. PubMed ID: 12888878
[TBL] [Abstract][Full Text] [Related]
33. Differential anti-thrombotic benefit and bleeding risk profiles of antagonists of protease-activated receptor 1 and 4 in Cynomolgus Macaques.
Wickham LA; Sitko G; Stranieri-Michener M; Handt L; Basso A; Fried S; Chu L; Maderia M; Owens K; Castriota G; Chen Z; Metzger JM; Imbriglio J; Wang X; Cai TQ
Thromb Res; 2016 Sep; 145():133-9. PubMed ID: 27318768
[TBL] [Abstract][Full Text] [Related]
34. Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway.
Holinstat M; Voss B; Bilodeau ML; Hamm HE
Mol Pharmacol; 2007 Mar; 71(3):686-94. PubMed ID: 17151288
[TBL] [Abstract][Full Text] [Related]
35. Protease-activated receptor 1 (PAR1) signalling desensitization is counteracted via PAR4 signalling in human platelets.
Fälker K; Haglund L; Gunnarsson P; Nylander M; Lindahl TL; Grenegård M
Biochem J; 2011 Jun; 436(2):469-80. PubMed ID: 21391917
[TBL] [Abstract][Full Text] [Related]
36. Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Li S; Tarlac V; Hamilton JR
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717963
[TBL] [Abstract][Full Text] [Related]
37. [Role of adenosine diphosphate in the course of thrombin signal transmission].
Han Y; Lu XX; Wang ZY; Dai L; Shen WH; Wu DP; Ruan CG
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(46):3299-301. PubMed ID: 17313817
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia.
Schoergenhofer C; Schwameis M; Gelbenegger G; Buchtele N; Thaler B; Mussbacher M; Schabbauer G; Wojta J; Jilma-Stohlawetz P; Jilma B
Thromb Haemost; 2018 Jul; 118(7):1176-1184. PubMed ID: 29864779
[TBL] [Abstract][Full Text] [Related]
39. Vorapaxar for the reduction of atherothrombotic events.
Diaz-Ricart M; Escolar G
Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
[TBL] [Abstract][Full Text] [Related]
40. Vorapaxar in the secondary prevention of atherothrombosis.
Tantry US; Liu F; Chen G; Gurbel PA
Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
